Fda approves takeda's eohilia (budesonide oral suspension), the first and only oral treatment in the u.s. for eosinophilic esophagitis (eoe)

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the u.s. food and drug administration (fda) has approved eohilia (budesonide oral suspension), the first and only fda-approved oral therapy for people 11 years and older with eosinophilic esophagitis (eoe).1 it will be available in 2 mg/10 ml convenient, single-dose stick packs by the end of february. eohilia is a corticosteroid indicated for 12 weeks of treatment in patients 11 years and older wit.
TAK Ratings Summary
TAK Quant Ranking